Case | Age / Gender | Eye | BCVA at baseline | BCVA at final visit | Follow up (months) | The time of PED occurrence | PEDA (degree) | CSC occurrence | Time between PED and CSC | PED outcomes | Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 46 / F | OD | 20/50 | 20/20 | 10 | Initial visist | 109.80 | No | - | Regression | Routine oral steroid tapering |
2 | 49 / F | OD | 20/200 | 20/20 | 13 | Initial visist | 101.82 | No | - | Regression | Routine oral steroid tapering & AZA |
3 | 34 / F | OD | 20/63 | 20/20 | 12 | Initial visit | 112.93 | No | - | Regression | Routine oral steroid tapering |
OS | 20/63 | 20/20 | 12 | Initial visit | 63.61 | No | - | Regression | Routine oral steroid tapering | ||
4 | 60 / F | OS | 20/40 | 20/33 | 7 | Initial visit | 133.87 | No | - | Regression | Routine oral steroid tapering |
5 (Fig. 2) | 40 / M | OS | 20/200 | 20/20 | 10 | Initial visit | 83.18 | Yes | 3 months | Persistence | Rapid oral steroid tapering & MMF subthreshold micropulse laser photocoagulation & continue-wave laser photocoagulation |
6 | 30 / F | OD | 20/40 | 20/40 | 18 | During follow-up | 89.60 | Yes | 6 months | Regression | Rapid oral steroid tapering & CsA & AZA & subthreshold micropulse laser photocoagulation |
7 | 58 / F | OD | 20/2000 | 0.2 | 6 | Initial visit | 125.73 | No | - | Regression | Intravenous methylprednisolone & oral tapering steroid & CsA |
8 | 62 / M | OS | 20/22 | 20/20 | 6 | During follow-up | 100.33 | No | - | Regression | Oral tapering steroid |
9 | 64 / M | OD | 20/200 | 20/28 | 9 | Initial visit | 59.92 | Yes | 2 months | Regression | Rapid oral steroid tapering & MMF |
10 (Fig. 3) | 47 / F | OD | 20/33 | 20/63 | 8 | Initial visit | 78.89 | Yes | 0 | Regression | Rapid oral steroid tapering off & CsA & MMF & ADA & subthreshold micropulse laser photocoagulation |
OS | 20/40 | 20/63 | 8 | Initial visit | 76.88 | Yes | 0 | Regression | Rapid oral steroid tapering off & CsA & MMF & ADA & subthreshold micropulse laser photocoagulation |